Cannabis and cannabinoids as therapeutic drugs;Cannabis und cannabinoide als medizin

Sucht

Volumn 48, Issue 5, 2002, Pages 329-335

  Stevens, Andreas ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Anorexia; Cannabinoids; Pain management; RTC

Indexed keywords

ANALGESIC AGENT; ANTIEMETIC AGENT; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR AGONIST; CANNABIS;

ANALGESIC ACTIVITY; ANOREXIA; ANTIEMETIC ACTIVITY; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG USE; EPILEPSY; GLAUCOMA; HUMAN; SPASTICITY; TRANQUILIZING ACTIVITY;

EID: 0036812046     PISSN: 09395911     EISSN: None     Source Type: Journal    
DOI: 10.1024/suc.2002.48.5.329     Document Type: Article

References (46)

1. Ameri, A. (1999). The effects of cannabinoids on the brain, Progres in Neurobiology, 58, 315-348.
2. Bachs, L., Morland, H. (2001). Acute cardiovascular fatalities following cannabis use. Forensic Science International, 124, 200-203.
3. Beal, J. E., Olson, R., Lefkowitz, L., Laubenstein, L., Bellman, P., Yangco, B., Morales, J. O., Murphy, R., Powderly, W., Plasse, T. F., Mosdell, K. W., Shepard, K. V. (1995). Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. Journal of Pain and Symptom Management, 10. 89-97.
4. Block, R. I., O'Leary, D.S., Ehrhardt, J. C., Augustinack, J. C., Ghoneim, M. M., Arndt, S., Hall, J. A. (2000). Effects of frequent marijuana use on brain tissue volume and composition. Neuroreport, 11, 491-496.
5. Block, R. I., Farinpour, R., Braverman, K. (1992). Acute effects of marijuana on cognition: Relationships to chronic effects and smoking techniques. Pharmacology Biochemistry and Behavior, 43, 907-917.
6. Block, R. I., Ghoneim, M. M. (1993). Effects of chronic marijuana use on human cognition. Psychopharmacology, 100, 219-228.
7. Bühler, B., Hambrecht, M., Löffler, W., van der Heiden, W., Häfner, H. (2002) Precipitation and determination of the onset and course of schizophrenia by substance abusea retrospective and prospective study of 232 population-based first illness episodes. Schizophrenia Research 54, 243-251.
8. Campbell, F. A., Tramer, M. R., Carroll, D., Reynolds, D. J., Moore, R. A., McQuay, H. J. (2001). Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. British Medical Journal, 323, 13-16.
9. Consroe, P., Laguna, J., Allender, J., Snider, S., Stern, L., Sandyk, R., Kennedy, K., Schram, K. (1991). Controlled clinical trial of cannabinol in Huntington's disease. Pharmacology Biochemistry and Behavior, 40, 701-708.
10. de-Fonseca, R. F., Carrera, M. R., Navarro, M., Koob, G. F., Weiss, F. (1997). Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science, 276, 2050-2054.
11. Degenhardt, L., Hall, W., Lynskey, M. (2001). Alcohol, cannabis and tobacco use among Australians: A comparison of their associations with other drug use and use disorders, affective and anxiety disorders, and psychosis. Addiction, 96, 1603-1614.
12. Ehrenreich, H., Rinn, T., Kunert, H. J., Moeller, M. R., Poser, W., Schilling, L., Gigerenzer, G., Hoehe, M. R. (1999). Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology, 142, 295-301.
13. Einhorn, L. H., Nagy, C., Furnas, B., Williams, S. D. (1981). Nabilone, an effective antiemetic in patients receiving cancer chemotherapy. Journal of Clinical Pharmacology, 9, 1314-1319.
14. Fabre, L. F., McLendon, D. (1981). The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety. Journal of Clinical Pharmacology, 21, 377-382.
15. Feldman, R. S., Meyer, J. S., Quenzer, L. F. (1997). Mind-Altering drugs. In: Principles of Neuropsychopharmacology, Sinauer Assoc., Mass., pp731-750.
16. Fox, S. H., Kellett, M., Moore, A. P., Crossman, A. R., Brotchie, J. M. (2002). Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Movement Disorders, 17, 145-149.
17. Gross, H., Ebert, M. H., Faden, V. B., Goldberg, S. C., Kaye, W. H., Caine, E. D., Hawks, R., Zinberg, N. (1983). A double-blind trial of delta-9-THC in primary anorexia nervosa. Journal of Clinical Pharmacology, 3, 165-171.
18. Hepler, R. S., Frank, I. M., Petrus, R. (1976). The ocular effects of marihuana smoking. In Braude, M.C., Szara, S. (Eds.), The Pharmacology of Marihuana. New York: Raven Press.
19. Ilaria, R. L., Thornby, J. I., Farm, W. E. (1981). Nabilone, a cannibinol derivative, in the treatment of anxiety neuroses. Current Therapeutic Research, 29, 943-949.
20. Iversen, L., Chapman, V. (2002). Cannabinoids: A real prospect for pain relief, Current Opinion in Pharmacology, 2, 50-55.
21. Jain, A. K., Ryan, J. R., McMahon, F. G., Smith, G. (1981). Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. Journal of Clinical Pharmacology, 21, 320-326.
22. Jones, S. E., Durant, J.R., Greco, F. A., Robertone, A. (1982). A multi-institutional phase III study of nabilone vs. Placebo in chemotherapy-induced nausea and vomiting. Cancer Treatment Reviews. 9, 45-48.
23. Lane, M., Vogel, C. L., Ferguson, J. (1991). Dronabinol and prochlorperazine in combination are better than either agent alone for treatment of chemotherapy-induced nausea and vomiting. Proceedings of the American Society of Clinical Oncology, 8, 326.
24. Levitt, M. (1986). Cannabinoids as antiemetic in cancer chemotherapy. In Mechoulam, R. (Ed.). Cannabinoids as Therapeutic Agents. Boca Raton FA: CRC Press.
25. Mass, R., Bardong, C., Kindl, K., Dahme, B. (2001). Relationship between cannbis use, schizotypal traits, and cognitive function in healthy subjects. Psychopathology, 34, 209-214.
26. Merritt, J. C., Crawford, W. J., Alexander, P. C., Anduze, A. L., Gelbart, S. S. (1980). Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmology, 87, 222-228.
27. Millsaps, C. L., Azrin, R. L., Mittenberg, W. (1994). Neuropsychological effects of chronic cannabis use on the memory and intelligence of adolescents. Journal of Child and Adolescent Substance Abuse, 3, 47-55.
28. Muller-Vahl, K. R., Koblenz, A., Jobges, M., Kolbe, H., Emrich, H. M., Schneider, U. (2001). Influence of treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta-9-THC) on neuropsychological performance. Pharmacopsychiatry, 34, 19-24.
29. Muller-Vahl, K. R., Schneider, U., Koblenz, A., Jobges, M., Kolbe, H., Daldrup, T., Emrich, H. M. (2002) Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): A randomized crossover trial. Pharmacopsychiatry 35, 57-61.
30. Navarro, M., Carrera, M. R., Fratta, W., Valverde, O., Cossu, G., Fattore, L., Chowen, J. A., Gomez, R., del Arco, I., Villanua, M. A., Maldonado, R., Koob, G. F., de Fonseca, F. R. (2001). Functional interaction between opioid and cannabinoid receptors in drug self-administration. Journal of Neuroscience, 21, 5344-5350.
31. Negrete, J. C., Gill, K. (1999). Cannabis and schizophrenia: An overview of the evidence to date. In Nahas, G. G., Sutin, K. M., Harvey, D., Agurell, S. (Eds.), Marihuana and Medicine (pp 671-682). Totowa NJ: Humana Press.
32. Niranen, A., Mattson, K. (1985). A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. American Journal of Clinical Oncology, 8, 336-340.
33. Noyes, R. (1975). The analgesic properties of delta-9-THC and codeine. Clinical Pharmacology and Therapeutics, 18, 84-89.
34. Orr, L. E., McKernan, J. G. (1981). Antiemetic effect of delta-9-THC in chemotherapy-associated nauseaa and emesis as compared to placebo and compazine. Journal of Clinical Pharmacology, 21, 76-80.
35. Petro, D. J., Ellenberger, C. (1981). Treatment of human spasticity with delta-9-THC. Journal of Clinical Pharmacology, 21, 413-416.
36. Piomelli, D., Giuffrida, A., Calignano, A., de Fonseca, F. R. (2000). The endocannabinoid system as a target for therapeutic drugs. Trends in Pharmacological Sciences, 21, 218-224.
37. Plasse, T. F., Gorter, R. W., Krasnow, S. H., Lane, M., Shepard, K. V., Wadleigh, R. G. (1991). Recent clinical experience with dronabinol. Pharmacology Biochemistry and Behavior, 40, 695-700.
38. Pomeroy, M., Fennelly, J. J., Towers, M. (1986). Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. Cancer Chemotherapy and Pharmacology, 17, 285-288.
39. Regelson, W. et al. (1976). Delta-9-THC as an effective antidepressant and appetite-stimulating agent in advanced cancer patients. In Braude MC, Szara S (Eds.) The Pharmacology of Marihuana (pp763-775). New York: Raven Press.
40. Robson, P. (2001). Therapeutic aspects of cannabis and cannabinoids. British Journal of Psychiatry, 178, 107-115.
41. Roth, M. D., Arora, A., Barsky, S. H., Kleerup, E. C., Simmons, M. S., Tashkin, D. P. (1998). Airway inflammation in young marijuana and tobacco smokers. American Journal of Respiratory and Critical Care Medicine, 157, 1-9.
42. Solowij, N. (1995). Do cognitive impairments recover following cessation of cannabis use? Life Sciences, 56, 2119-2226.
43. Tashkin, D. P., Reiss, S., Shapiro, B. J., Calvarese, B., Olsen, J.L., Lodge, J.W. (1977). Bronchial effects of aerosolized delta-9-THC in healthy and asthmatic subjects. American Reviews of Respiratory Disease, 115, 57-65.
44. Ungerleider, J. T., Andrysiak, T., Fairbanks, L., Goodnight, J., Sarna, G., Jamison, K. (1982). Cannabis and cancer chemotherapy: A comparison of oral delta-9-THC and prochlorperazine. Cancer, 50, 636-645.
45. Volkow, N. D., Gillespie, H., Mullani, N., Tancredi, L., Grant, C., Valentine, A., Hollister, L. (1996). Brain glucose metabolism in chronic marijuana users at baseline and during marijuana intoxication. Psychiatry Research Neuroimaging, 67, 29-38.
46. Watson, S. J., Benson, J. A., Joy, J. E. (2000). Marijuana and medicine: Assessing the science base. A summary of the 1999 Institute of Medicine report. Archives of General Psychiatry, 57, 547-552.